Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Post-Marketing Safety Studies Could Be Funded By User Fees, Cmte. Suggests

Executive Summary

User fees to fund post-marketing safety assessments should be considered in negotiations for the reauthorization of the Prescription Drug User Fee Act, a former FDA official and member of the Drug Safety & Risk Management Advisory Committee suggested

You may also be interested in...

Drug Safety Bill Authorizes Fines On Industry, But Does Not Include User Fees

The Center for Postmarket Drug Evaluation & Research proposed in legislation from Sens. Grassley and Dodd would be funded by appropriations, not user fees

FDA Safety Act Calls For “Expedited Procedures” For Drug Withdrawals

Postmarketing safety legislation proposed by Senate Finance Committee Chairman Charles Grassley (R-Iowa) and Sen. Chris Dodd (D-Conn.) calls for FDA to establish "expedited procedures" for drug withdrawals

Phase IV Status Report: Fewer Open Studies, But More Overdue Reports

The pharmaceutical industry had 67% fewer drugs and biologics with open Phase IV commitments in fiscal year 2004 than the previous year, FDA's postmarketing database shows





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts